Sientra (NASDAQ:SIEN) had its price objective raised by Lake Street Capital from $11.00 to $13.00 in a research report sent to investors on Thursday morning, MarketBeat Ratings reports. They currently have a hold rating on the medical instruments supplier’s stock.

A number of other research analysts also recently weighed in on the company. Stifel Nicolaus upgraded Sientra from a hold rating to a buy rating and set a $14.00 price target on the stock in a report on Friday, January 19th. Zacks Investment Research downgraded Sientra from a buy rating to a hold rating in a report on Saturday, March 17th. BidaskClub downgraded Sientra from a hold rating to a sell rating in a report on Tuesday, January 9th. Canaccord Genuity reiterated a buy rating and set a $19.00 price target on shares of Sientra in a report on Friday, January 5th. Finally, ValuEngine downgraded Sientra from a hold rating to a sell rating in a report on Thursday, February 22nd. One analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company. The company has an average rating of Buy and a consensus price target of $13.83.

Shares of NASDAQ SIEN opened at $12.84 on Thursday. Sientra has a 52-week low of $7.20 and a 52-week high of $16.68. The firm has a market capitalization of $235.33, a P/E ratio of -4.55 and a beta of -1.06.

Sientra (NASDAQ:SIEN) last issued its quarterly earnings results on Tuesday, March 13th. The medical instruments supplier reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.21). Sientra had a negative net margin of 175.22% and a negative return on equity of 107.35%. The business had revenue of $11.10 million for the quarter, compared to analysts’ expectations of $11.90 million. During the same quarter in the prior year, the firm posted ($0.43) EPS. The business’s quarterly revenue was up 70.8% compared to the same quarter last year. analysts anticipate that Sientra will post -2.63 earnings per share for the current fiscal year.

A number of hedge funds and other institutional investors have recently modified their holdings of the business. BlackRock Inc. grew its stake in Sientra by 4.9% in the fourth quarter. BlackRock Inc. now owns 758,512 shares of the medical instruments supplier’s stock valued at $10,664,000 after purchasing an additional 35,429 shares in the last quarter. Senzar Asset Management LLC grew its stake in Sientra by 271.6% in the fourth quarter. Senzar Asset Management LLC now owns 484,607 shares of the medical instruments supplier’s stock valued at $6,814,000 after purchasing an additional 354,200 shares in the last quarter. X Square Capital LLC purchased a new position in Sientra in the fourth quarter valued at about $2,232,000. State Street Corp purchased a new position in Sientra in the second quarter valued at about $1,449,000. Finally, Allianz Asset Management GmbH purchased a new position in Sientra in the third quarter valued at about $1,098,000. Hedge funds and other institutional investors own 77.38% of the company’s stock.

WARNING: This news story was posted by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this news story on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The original version of this news story can be read at https://www.thecerbatgem.com/2018/04/22/sientra-sien-price-target-raised-to-13-00.html.

About Sientra

Sientra, Inc, a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, Dermaspan, Softspan, and BIOCORNEUM brand names.

Analyst Recommendations for Sientra (NASDAQ:SIEN)

Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.